Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
7 studies found for:    "Rhabdomyosarcoma alveolar"
Show Display Options
Rank Status Study
1 Active, not recruiting Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma
Conditions: Adult Rhabdomyosarcoma;   Childhood Alveolar Rhabdomyosarcoma;   Childhood Anaplastic Rhabdomyosarcoma;   Childhood Mixed Alveolar Rhabdomyosarcoma;   Previously Treated Childhood Rhabdomyosarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Childhood Rhabdomyosarcoma
Interventions: Drug: Vinorelbine Tartrate;   Drug: Cyclophosphamide;   Biological: Bevacizumab;   Drug: Temsirolimus;   Other: Laboratory Biomarker Analysis
2 Active, not recruiting
Has Results
Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma
Conditions: Neuroblastoma;   Sarcoma;   Rhabdomyosarcoma-Embryonal;   Rhabdomyosarcoma- Alveolar;   Neuroectodermal Tumors, Primitive, Peripheral
Interventions: Drug: Tumor Purged/CD25 Depleted Lymphocytes;   Biological: Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine;   Drug: rhIL-7;   Biological: Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine
3 Recruiting CREATE: Cross-tumoral Phase 2 With Crizotinib
Conditions: Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma;   Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor;   Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1;   Locally Advanced and/or Metastatic Alveolar Soft Part Sarcoma;   Locally Advanced and/or Metastatic Clear Cell Sarcoma;   Locally Advanced and/or Metastatic Alveolar Rhabdomyosarcoma
Intervention: Drug: Crizotinib (PF-02341066)
4 Active, not recruiting Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma
Conditions: Adult Rhabdomyosarcoma;   Childhood Alveolar Rhabdomyosarcoma;   Childhood Embryonal Rhabdomyosarcoma;   Metastatic Childhood Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma;   Untreated Childhood Rhabdomyosarcoma
Interventions: Biological: Cixutumumab;   Drug: Doxorubicin Hydrochloride;   Drug: Irinotecan Hydrochloride;   Drug: Vincristine Sulfate Liposome;   Drug: Ifosfamide;   Drug: Etoposide;   Drug: Cyclophosphamide;   Biological: Dactinomycin;   Drug: Temozolomide;   Other: Laboratory Biomarker Analysis
5 Active, not recruiting Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
Conditions: Adult Angiosarcoma;   Adult Desmoplastic Small Round Cell Tumor;   Adult Epithelioid Sarcoma;   Adult Extraskeletal Myxoid Chondrosarcoma;   Adult Extraskeletal Osteosarcoma;   Adult Fibrosarcoma;   Adult Leiomyosarcoma;   Adult Liposarcoma;   Adult Malignant Mesenchymoma;   Adult Malignant Peripheral Nerve Sheath Tumor;   Adult Rhabdomyosarcoma;   Adult Synovial Sarcoma;   Adult Unclassified Pleomorphic Sarcoma of Bone;   Childhood Anaplastic Rhabdomyosarcoma;   Childhood Angiosarcoma;   Childhood Desmoplastic Small Round Cell Tumor;   Childhood Epithelioid Sarcoma;   Childhood Fibrosarcoma;   Childhood Leiomyosarcoma;   Childhood Liposarcoma;   Childhood Malignant Mesenchymoma;   Childhood Malignant Peripheral Nerve Sheath Tumor;   Childhood Mixed Alveolar Rhabdomyosarcoma;   Childhood Synovial Sarcoma;   Dermatofibrosarcoma Protuberans;   Malignant Adult Hemangiopericytoma;   Malignant Childhood Hemangiopericytoma;   Metastatic Childhood Soft Tissue Sarcoma;   Previously Treated Childhood Rhabdomyosarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma;   Untreated Childhood Rhabdomyosarcoma
Interventions: Biological: Cixutumumab;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis
6 Recruiting Studying Protein Expression in Tissue Samples From Younger Patients With Rhabdomyosarcoma
Conditions: Alveolar Childhood Rhabdomyosarcoma;   Embryonal Childhood Rhabdomyosarcoma;   Previously Treated Childhood Rhabdomyosarcoma;   Previously Untreated Childhood Rhabdomyosarcoma;   Recurrent Childhood Rhabdomyosarcoma
Intervention: Other: laboratory biomarker analysis
7 Unknown  Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features
Conditions: Carcinoid;   Neuroendocrine
Intervention: Drug: Seneca Valley Virus (biological agent)

Indicates status has not been verified in more than two years